FDA offers final guidance on transferring clinical investigation oversight

By Zachary Brennan

- Last updated on GMT

Related tags: Institutional review board, Irb

FDA offers final guidance on transferring clinical trial oversight
The US FDA has issued final guidance on the transferring of clinical studies between IRBs (institutional review boards) in order to help ensure that serious disruptions in clinical trials are rare.

The guidance discusses the regulatory responsibilities of IRBs, clinical investigators, and sponsors when oversight of a previously approved, ongoing clinical investigation under FDA’s jurisdiction is transferred from one IRB to another IRB.

The transfer of review responsibility for a clinical investigation from one IRB to another “should be accomplished in a way that assures continuous IRB oversight with no lapse in either IRB approval or the protection of human subjects, and with minimal disruption of research activities,” the FDA says.

Such transfers of oversight may occur for a number of different reasons, such as cessation of IRB operations, consolidation of multiple IRBs into a single IRB, temporary inability of an IRB to meet its obligations, or as a result of IRB non-compliance.

The guidance provides recommendations concerning the transfer of IRB oversight from one IRB to another IRB that is not part of the same institution and recommends the transfer process be documented in a written agreement.

Such an agreement should address the studies that are being transferred; all pertinent records, such as the research protocol and significant amendments. Under FDA regulations, IRB records related to the review of a clinical investigation must be retained for at least three years after the completion of the research, and the records must be accessible for inspection and copying by FDA.

Other items worth considering in an agreement include the date for the transfer, whether consent forms need to be revised, notification of the key parties and an update of the IRB registration information.

The guidance also addresses the transfer of oversight from one IRB to another IRB operating within the same institution, the temporary transfer of clinical investigation oversight to another IRB that occurs as a result of a natural disaster or for other reasons, and the transfer of a clinical investigation to a new research site requiring IRB review.

The IRB guidance comes as the FDA has previously focused its efforts on IRB responsibilities​ in checking investigator qualifications, ensuring sites are up to code, and investigating whether an IND is necessary for a proposed trial. 

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more